Opioid Use Disorder

New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs. standard initiation among patients with opioid use disorder, according to a press release.

Drug overdose deaths decreased slightly in 2023 compared with the previous year but still remain at a near-historic high, according to an AMA report.

Although state laws have expanded access to naloxone, overdose deaths among adolescents and young adults continue to climb, according to data published in JAMA Pediatrics.

A community coalition-engaged intervention led to a statistically significant reduction in overdose deaths involving any opioid and psychostimulants other than cocaine, according to a study published in JAMA Network Open.

Individuals receiving methadone for opioid use disorder had a lower risk for discontinuing treatment compared with the combination of buprenorphine and naloxone, study results published in JAMA showed.

Ozempic and similar drugs for diabetes and weight-related conditions were associated with a 40% lower rate of opioid overdose and 50% lower rate of alcohol intoxication in people with opioid and alcohol use disorders, a new study showed.

Buprenorphine use increased in EDs over the last decade but remained underused after opioid-related encounters, a cross-sectional study published in JAMA Network Open suggested.

Higher doses of buprenorphine were associated with significantly lower rates of acute care utilization among adults with opioid use disorder compared with the FDA’s recommended dose, according to a study published in JAMA Network Open.

Fatal and nonfatal drug overdoses experienced “unprecedented” decreases of 10% to 20% from last year, which could be due to factors like increased naloxone availability, according to researchers.

ORLANDO — In this Healio video perspective, AAP president Benjamin D. Hoffman, MD, FAAP, discusses new policy statements at the AAP National Conference & Exhibition.